Delivery Order SPE2DB25D3202-SPE2DB25FTBCT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,661.03 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL). This is a firm fixed price delivery order with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) pre-filled pens with a ceiling value of $3,519.05. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at $18,198.96 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3mL vials. The contract was competitively awarded with firm fixed pricing and is scheduled for completion by August 13, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $15,411.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pen 3ml formulations. The contract was competitively awarded without a set-aside designation and is scheduled for completion by July 24, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is issued under the company's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a $13,541.70 delivery order to AmerisourceBergen Drug Corp for Ozempic (0.25-0.5 mg/dose pen, 3ml) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,779.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price terms and specifies Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,308.27 to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pen 3ml on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml) with a ceiling value of $26,032.94. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,399.90. This competitive award, executed under a firm fixed-price delivery order contract type with no set-aside designation, is set to conclude by July 29, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,819.97 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBCTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,361.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitive award uses firm fixed pricing with no set-aside designation and is scheduled for completion by August 12, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare systems worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and maintains an extensive portfolio of brand-name and generic medications across multiple therapeutic domains. The company's contract awards with DLA demonstrate its capability to meet federal procurement requirements through open competition, with this Ozempic order supporting diabetes treatment needs within the Defense Health Agency and broader military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/11/25 |